ClinicalTrials.gg
RecruitingNCT02823366Updated Oct 30, 2026

Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid

A Phase 3 interventional study of Fenofibrate and UDCA in Primary Biliary Cirrhosis, sponsored by Xijing Hospital of Digestive Diseases. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Xijing Hospital of Digestive Diseases · Phase 3, Interventional, and Treatment

How we know

Updated Oct 30, 2026Now RecruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies testing fenofibrate in Liver Cirrhosis, Biliary — 7 open to participants now, 9 under way, 8 of them phase 3. Fenofibrate · Liver Cirrhosis, Biliary.

Planned enrollment
8th of 13
104 · median 117
Started
2016
with 2 others
Phase 3
6 of 13
5 open now
Registered
2nd of 13
by date
Lead sponsor
9 of 13
Xijing Hospital of Digestive Diseases

Among the 13 studies testing fenofibrate in Liver Cirrhosis, Biliary, this one is the 8th largest by planned enrollment, is one of 3 that started in 2016, is one of 6 in phase 3, and was the 2nd registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

7 of the 13 studies testing fenofibrate in Liver Cirrhosis, Biliary are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

About fenofibrate

Fenofibrate: first FDA approval 1993 (TRICOR (MICRONIZED)), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing fenofibrate in Liver Cirrhosis, Biliary, or all of them as a file.
02

Study summary

Ursodeoxycholic acid (UDCA) has been the only treatment for PBC approved by US and European drug administrations. Long-term use of UDCA(13-15 mg/kg/day) in patients with PBC improves serum liver biochemistries and survival free of liver transplantation However, about 40% of patients do not respond to UDCA optimally as assessed by known criteria for biochemical response. Those patients represent the group in need for additional therapies, having increased risk of disease progression and decreased survival free of liver transplantation. Both lab research and some clinical studies suggest that fenofibrate could improve cholestasis in multiple ways including reduce of bile acid synthesis, increase of biliary secretion and anti-inflammation effect. Here we start a random, open and parallel clinical research to explore the effect of fenofibrate in the PBC treatment.

03

Conditions studied

  • Primary Biliary Cirrhosis

Keywords

  • PBC
  • UDCA
  • Fenofibrate
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed
  2. Patient with PBC defined by 2 in 3 of the following criteria: a.Positive antimitochondrial antibody type M2; b.Abnormal serum alkaline phosphatases (ALP > 1,5N) and aminotransferase ( or ALT > 1N) activities; c.Histological hepatic injuries consistent with PBC.
  3. Had been treated with UDCA more than 6 months, and failed to achieve a complete biochemical response.

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy or desire of pregnancy.
  2. Breast-feeding.
  3. Co-existing liver diseases such as acute or chronic viral hepatitis, alcoholic liver disease, choledocholithiasis, hepatitis, -proven non-alcoholic fatty liver disease, Wilson's disease and hemochromatosis.
  4. History or presence of hepatic decompensation (e.g., variceal bleeds, encephalopathy, or poorly controlled ascites).
  5. History of urolithiasis, nephritis or renal failure (clearance of creatinine \< 60 ml/mn).
  6. Hepatotoxic drugs use before recruiting.
  7. Fenofibrate anaphylaxis.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    Fenofibrate + UDCA

    Fenofibrate in combination with ursodeoxycholic acid

    Drug: Fenofibrate · Drug: UDCA

  • Active comparator
    Monotherapy

    UDCA alone

    Drug: UDCA

Interventions

06

What researchers measure

Primary outcomes

  1. Rate of patients with complete biochemical response

    Normalization of alkaline phosphatase (ALP) or decrease of ALP by more than 40% compared to the baseline.

    Time frame: Week 24

Secondary outcomes

  1. Change in liver biopsy examinations according to conventional Ludwig system.

    Histological evolution will be checked by liver biopsy at the end of the study to compare with baseline histological status. The Ludwig histological classification schemes will be used, which categorised the disease into four stages.

    Time frame: Week 48

  2. Change in GLOBE risk scores after treatment.

    The prognostic scores will be calculated at entry and end of study by GLOBE scoring system, which calculated based on serum values of bilirubin, ALP, albumin and platelet count after 1 year of treatment and age at baseline.

    Time frame: Week 48

  3. Change in liver stiffness status measured by magnetic resonance elastography.

    The change of liver stiffness status at the end of the study compared to baseline checked by magnetic resonance elastography.

    Time frame: Week 48

  4. Change in serum levels of ALP compared to the baseline.

    Absolute change in serum levels of ALP compared to the baseline.

    Time frame: Weeks 0, 4, 8, 12, 24, and 48

  5. Change in serum levels of bilirubin compared to the baseline.

    Absolute change in serum levels of bilirubin compared to the baseline.

    Time frame: Weeks 0, 4, 8, 12, 24, and 48

  6. Change in serum levels of transaminase compared to the baseline.

    Absolute change in serum levels of transaminase compared to the baseline.

    Time frame: Weeks 0, 4, 8, 12, 24, and 48

Other outcomes

  1. Change in symptom-pruritus.

    The symptom of pruritus will be evaluated by questionnaire before enrolment and at the end of the study.

    Time frame: Week 24

  2. Change in symptom-fatigue.

    The symptom of fatigue will be evaluated by Fatigue Impact Scale before enrolment and at the end of the study.

    Time frame: Week 24

  3. Change in serum Immunoglobulin M Levels.

    Absolute change in serum levels of Immunoglobulin M compared to the baseline.

    Time frame: Week 24

07

Study locations

1 of 1 sites recruiting
  • Xijing Hosipital
    Xi'an, Shaanxi 710032, China
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimatedDate before it movedWhere the date was before it moved

The record gives a start of Jan 2016, a primary completion of Dec 2028 and a completion of Dec 2028. It does not say whether these dates are actual or estimated.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Dec 2023 → Dec 2028 and completion Dec 2023 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2016
First posted
Jul 6, 2016
Start
Jan 2016
Primary completionEst.
Dec 2028was Dec 2023
CompletionEst.
Dec 2028was Dec 2023
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Recruiting
changed Oct 30, 2026
Primary completion
Dec 2023→Dec 2028
Oct 30, 2026
Study completion
Dec 2023→Dec 2028
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Status unknown→Recruiting
    Primary completion Dec 2023→Dec 2028
    Study completion Dec 2023→Dec 2028
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT02823366
Lead sponsor
Xijing Hospital of Digestive Diseases
Responsible party
Han Ying (Professor Consultant Physician, Xijing Hospital of Digestive Diseases) — Principal investigator
First posted
Jul 6, 2016
Start date
Jan 2016
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 30, 2026

Study contacts

Ying Han, Ph.D
Contact
hanying@fmmu.edu.cn
86-29-84771539
Yongquan Shi, Ph.D
Contact
shiyquan@fmmu.edu.cn
86-29-84771515
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fenofibrate

Start the discussion